A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Bleximenib
DRUG: Venetoclax (VEN)
DRUG: Azacitidine (AZA)
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC